OEP
Our Mission
About OEP

Founded in 1982, Orient EuroPharma Co., Ltd (OEP) was officially listed in the Gre-Tai Securities market in 2003, and consolidated net sales exceeded $5 billion in the 2014 financial year. Currently, OEP has more than 800 staffs worldwide, in which over 40% are overseas employees. OEP’s products include pharmaceuticals, cancer drugs, cosmeceutical, infant & adult nutrition and healthcare products. OEP also established a subsidiary company focused on developing and manufacturing new drugs. OEP is one of multinational pharmaceutical companies able to integrate pharmaceutical research & development, clinical trial, manufacture and marketing in Taiwan.

In 2013, OEP was named 2nd Benchmark Pharmaceutical Company in 2013 The Leading Biomedical Businesses of Taiwan by the Institute for Biotechnology and Medicine Industry. CommonWealth Magazine also placed OEP among the top 2000 large enterprises since 2012. In 2015, Listed as one of the top 100 businesses that the new generation most aspires to work for by Cheers: Happy Workers magazine.

OEP collaborated with multinational pharmaceutical companies to sell prescription drugs for five major treatments areas, including cardiovascular, cancer, central neuroscience system, respiratory, and hormones. For infant nutrition, OEP collaborated with New Zealand’s Dairy Goat Co-operatives (DGC) to market a new goat milk powder brand, Karihome. Karihome has successfully entered the China and Southeast Asia market, and is one of the few Taiwanese companies able to manage an international brand.

With the globalizing and growing market, OEP started to establish overseas subsidiaries in Singapore, Malaysia, Hong Kong and the Philippines since 1993. In 2006, OEP established the subsidiaries in Shanghai and Guangdong. In 2011, OEP expanded its market to Vietnam and planned to expand to Sri Lanka, Cambodia, Myanmar and India, strengthening OEP’s marketing and sales capability in the Asian Pacific region.

The subsidiary company OrientPHARMA Co., Ltd (OP) was founded in 2008 for developing and manufacturing new drugs. The OP plant is allocated in Huwei Park in Yunlin and has got the certifications of Taiwan PIC/S GMP, the “Accreditation Certification of Foreign Drug Manufacturer” from Japan MHLW, and US FDA international standards. Its progressive air-conditioning, water purification, air-compression and maintenance systems are capable of preventing plant and equipment cross contamination, and conform to international professional pharmaceutical standards for the next three decades.

In 2012, OEP expanded its R&D capabilities in the cancer drug area, and signed an agreement with Japan NanoCarrier Co., Ltd. to jointly develop new cancer drugs. In 2013, OPNano Co., Ltd was established, and the new injection plant began construction in 2014.

Mission and Vision
The core values of Orient EuroPharma Co., Ltd are Integrity, Solidarity and Innovation. Consistent with its corporate culture of “Practice Trustworthy, Show Honesty, Establish Communication, Demonstrate Caring, Exercise Creativity, and Partake Development,” the company strives to fulfill the mission of “enhancing health and beauty” and the pursuit of corporate growth.
Orient EuroPharma Co., Ltd aims to step beyond Asia to become a global pharmaceutical industry. Built on understanding and meeting the real needs of people, genuine care, active research and development, Orient EuroPharma Co., Ltd collaborates with internationally pharmaceutical companies to develop brand products with market potential and autonomy to continue offering value and services to our customers.

 

Company History
1982

Founded Orient EuroPharma Co., Ltd

1989

Imported infant goat formula from New Zealand, and created the Karihome brand for domestic sales in Taiwan

1999

Invested in the GMP pharmaceutical plant, gradually establishing subsidiaries in locations such as Singapore, Malaysia and Hong Kong

2002

1.Purchased farms in New Zealand, becoming the first Taiwan goat milk supplier with approved membership in the New Zealand Dairy Board.

1.Purchased farms in New Zealand, becoming the first Taiwan goat milk supplier with approved membership in the New Zealand Dairy Board. 2. Established new offices in Philippines, further expanding the Company’s Southeast Asian territory.

3.Established the medical cosmetics department.

2003

1.Officially listed for OTC trading.

2.Imported Swedish injectable hyaluronic acid products, becoming the first company in Taiwan to obtain government permit for brands with hyaluronic acid.

2004

「Karihome」 series marketed in Hong Kong.

2008

Established subsidiary company, OirentPHARMA Co., Ltd

「Karihome」 series marketed in Guangdong, China.

2009

OirentPHARMA Co., Ltd approved as a biotechnology and pharmaceutical company by the Industrial Development Bureau, Ministry of Economic Affairs, and under biotechnology and pharmaceutical industry regulations, qualified for special research and development and training grants.

2010

Established offices in Vietnam, enhancing Southeast Asian channels.

2011

1.OirentPHARMA Co., Ltd awarded Taiwan’s Food and Drug Administration PIC/S GMP certification.

2. OirentPHARMA Co., Ltd approved and in effect for public listing

2012

1.OirentPHARMA Co., Ltd awarded Japan’s official foreign pharmaceutical manufacturer certification.

2.OirentPHARMA Co., Ltd officially listed for OTC trading.

3.Signed agreement with Japan’s NanoCarrier Co., Ltd. to develop new pancreatic cancer drug and construct a new plant.

2013

1. OirentPHARMA Co., Ltd awarded U.S. Food and Drug Administration Manufacturing Plant Inspection certification.

2. 「Karihome」cow series marketed in China

2014

OP Nano Co,. Ltd was established, and the new injection plant began construction.

Awards
2007

OirentPHARMA Co., Ltd achieved class A+ for the 4th annual Information Enclosure Evaluation.

2009

Karihome Goat Milk of Orient Pharma led for many years in the TNS model market survey.

2010

OirentPHARMA Co., Ltd achieved class A+ for the 7th annual Information Enclosure Evaluation.

2011

1.OirentPHARMA Co., Ltd achieved class A+ for the 8th annual Information Enclosure Evaluation.

2. Honored with the 1st Gre Tai Securities Market Golden laurel Award for excellent and sustainable enterprise.

2012

Ranked 600th among the top thousand large enterprises named by the CommonWealth Magazine.

2013

1. Ranked 549th among the top two thousand large enterprises named by the CommonWealth Magazine.

2. OirentPHARMA Co., Ltd achieved class A+ for the 10th annual Information Enclosure Evaluation.

3. OEP named as one of the top three benchmark biotechnology by the Institute for Biotechnology and Medicine Industry.

4. OrientPHARMA Co., Ltd won excellent award for pharmaceutical Good Distribution Practice (GDP) certification from Taiwan FDA

2014

1. Ranked 538th among the top two thousand large enterprises named by the CommonWealth Magazine

2. Orient EuroPharma Co., Ltd achieved class A+ for 11th annual information enclousre Evalutaion.

2015

1. Ranked 526th among the top two thousand large enterprises named by the CommonWealth Magazine.

2. Orient EuroPharma Co., Ltd was named again as one of Benchmark Pharmaceutical Company (Bio Taiwan Highlight) By IBMI (Institute for Biotechnology and Medicine Industry)

2016

1. Orient EuroPharma Co., Ltd was ranked 61 among the top one hundred bio-tech stock named by the BusinessToday Magazine.

2. OrientPHARMA Co., Ltd was ranked 68 among the top one hundred bio-tech stock named by the BusinessToday Magazine.